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“I stand at the seashore, alone, and start to think. There are the 
rushing waves ... mountains of molecules, each stupidly minding its 
own business ... trillions apart ... yet forming white surf in unison. 
Ages on ages ... before any eyes could see ... year after year ... 
thunderously pounding the shore as now. For whom, for what? ... on 
a dead planet, with no life to entertain. 
Never at rest ... tortured by energy ... wasted prodigiously by the 
sun ... poured into space. A mite makes the sea roar. 
Deep in the sea, all molecules repeat the patterns of one another 
till complex new ones are formed. They make others like themselves 
... and a new dance starts. 
Growing in size and complexity ... living things, masses of atoms, 
DNA, protein ... dancing a pattern ever more intricate. 
Out of the cradle onto the dry land ... here it is standing ... atoms 
with consciousness ... matter with curiosity. 
Stands at the sea ... wonders at wondering ... I ... a universe of 
atoms ... an atom in the universe. ” 
"The Value of Science" 
 Richard P. Feynman 
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1.1 MMP-13 and the Osteoartrite (OA) desease  
 
Osteoarthritis (OA) is the leading cause of joint pain and disability in 
middle-aged and elderly patients. It is characterized by progressive loss of 
articular cartilage that eventually leads to denudation of the joint surface. 
The cartilage loss observed in OA is the result of a complex process 
involving degradation of various components of the cartilage matrix. 
Particularly, degradation of cartilage-specific type II collagen by 
mammalian collagenases (MMPs) is a key step in the loss of structural and 
functional integrity of cartilage.1 Among all known MMPs, MMP-13 is 
considered the principal target in OA. Indeed, today there are 
overwhelming data on the role of MMP-13 in the pathogenesis of OA,2 and 
inhibition of its activity has proven to be efficacious in a variety of models 
of experimentally induced as well as spontaneously occurring OA.3 
Unfortunately, none of the known MMP inhibitors (MMPIs) have been 
successfully utilized as therapeutic agents so far. This was due to the lack 
of selectivity for a specific isozyme, leading to heavy dose- and duration-
dependent musculoskeletal side effects.4 Therefore, current drug 
development strategies for treatment of OA are focused on selective 
inhibition of MMP-13, although recent evidences suggest that other 
MMPs, such as MMP-1, may also contribute to the collagen degradation 
process.5 However, the design of a selective MMPI is not a trivial task, as 
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MMPs share an high similarity in the overall three-dimensional fold and 
many conserved amino acids exist in the inhibitor binding site, besides the 
conserved catalytic zinc ion. The major structural difference observed 
between the MMP enzymes resides in the relative size and shape of the S1’ 
subsite, which is located in proximity of the catalytic metal. From a 
structural point of view, almost all MMPIs known so far are based on a 
zinc-binding group (ZBG) and a hydrophobic portion protruding into the 
hydrophobic S1’ subsite. These compounds behave as competitive 
inhibitors since the ZBG can mimic one of the transition states occurring 
during the substrate hydrolysis. Currently, two successful strategies to 
confer selectivity of action to an MMP inhibitor are known: the first resides 
in the proper modification of the P1’ substituent on MMPI to take 
advantage of the differences between the diverse MMPs; the second is the 
finding of an allosteric inhibitor,6 which binds tightly to the S1’ and S1’* 
subsite without chelating the metal that is thought to contribute to the 
promiscuous inhibition of multiple MMPs.Errore. Il segnalibro non è definito.c 
Recently, as a result of the first strategy, it has been designed a N-
isopropoxy-arylsulfonamide-based hydroxamate inhibitor, which showed 
low nanomolar activity for MMP-13 and high selectivity over some other 
tested MMPs.7 In parallel to further studies aiming to assess the activity of 
this promising compound using in vivo models of OA, it has been decided 
to seek for novel scaffolds as allosteric inhibitors on one hand, and as zinc-
chelating non-hydroxamate inhibitors on the other. In fact, a debate is still 
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open on the advisability of using hydroxamates as ZBG due to toxicity and 
metabolic stability issues.8,9  
In this respect, we have taken advantage of the availability of several 
MMP-13 crystal structures and have used two different in silico methods to 
screen the Life Chemicals and the Maybridge databases, respectively. 
Experimental tests of a limited selection of candidate compounds (60) 
verified nine novel leads, structurally unrelated to the known MMPIs. 
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1.2 MMPs: Definition, Function and Regulation. 
 
Matrix metalloproteinases (MMPs) are a family of extracellular zinc-
dependent neutral endopeptidases collectively capable of degrading 
essentially all ECM components and they play an important role in ECM 
remodeling in physiologic situations, such as embryonal development, 
tissue regeneration, and wound repair. MMPs also play a role in 
pathological conditions involving untimely and accelerated turnover of 
ECM, including rheumatoid arthritis, osteoarthritis, atherosclerotic plaque 
rupture, aortic aneurysms, periodontitis, autoimmune blistering disorders of 
the skin, dermal photoaging, and chronic ulcerations. In addition, distinct 
MMPs play important, and sometimes opposite roles at different steps of 
tumor growth, invasion, and metastasis, and recent observations suggest 
that MMPs also play a role in cancer cell survival. 
The human MMP gene family consists of more than 25 structurally 
related members that fall into five classes according to their primary 
structure and substrate specificity: collagenases (MMP-1, MMP-8, and 
MMP-13), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3, 
MMP-7, MMP-10, MMP-11, and MMP-12), membrane type (MT)-MMPs 
(MT1-MMP, MT2- MMP, MT3-MMP, and MT4-MMP), and nonclassified 
MMPs10. The proteolytic activity of MMPs is inhibited by nonspecific 
protease inhibitors, such as α2-macroglobulin and α1- antiprotease, and by 
the specific tissue inhibitors of the metalloproteinases (TIMPs). The TIMPs 
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are a family of four structurally related proteins (TIMP-1, -2, -3, and -4), 
which exert a dual control on the MMPs by inhibiting both the active form 
of the MMPs and their activation process. The TIMPs inhibit the enzymatic 
activity of all members of the MMP family (with the exception of MT1-
MMP, which is inhibited by TIMP-2 and -3 but not by TIMP-1) by 
forming noncovalent stoichiometric complexes with the active zinc-
binding site of the MMPs.11 
The general structure of the MMPs includes a signal peptide, a 
propeptide domain, a catalytic domain with a highly conserved zinc-
binding site, and a haemopexin-like domain that is linked to the catalytic 
domain by a hinge region. In addition, MMP-2 and MMP-9 contain 
fibronectin type II inserts within the catalytic domain, and MT-MMPs 
contain a transmembrane domain at the C-terminal end of the haemopexin-
like domain. The haemopexin domain is absent in the smallest MMP, like 
matrilysin (MMP-7). 
Most MMPs are secreted as latent precursors (zymogens) that are 
proteolytically activated in the extracellular space. The pro-MMPs are 
retained in their inactive form by an interaction between a cysteine residue 
located in the propeptide portion of the molecule with the catalytic zinc 
atom, blocking the access of substrates to the catalytic pocket of the 
enzyme. Partial proteolytic cleavage of the propeptide dissociates the 
covalent bond between the cysteine residue and the catalytic site and 
exposes the catalytic site to the substrate. MMPs are activated in an orderly 
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fashion, with one activated MMP cleaving and activating the next in a 
complex and only partially deciphered network of proteases in the 
extracellular space.12 
The catalytic domain is folded into a single globular unit 
approximately 35 Å in diameter and the structure is dominated by a single 
five-stranded β–sheet with one antiparallel and four parallel strands and 
three α-helices. The catalytic domain contains two tetrahedrally–
coordinated Zn2+ ions: a “structural” zinc ion and a “catalytic” zinc ion 
whose ligands include the side chains of the three histidyl residues in the 
conserved HEXXHXXGXXH sequence.  
To date, eighteen X-ray structures of MMP-13 catalytic domain have 
been released in the Protein Data Bank. Besides that co-crystallized with 
TIMP-2 (PDB code: 2E2D), all the others were co-crystallized with 
organic inhibitors. A superposition of all X-ray structures on the alpha 
carbon atoms, using 830C as reference structure, shows that the protein 
folding and the catalytic loops shape are highly superimposable. 
Intriguingly, the analysis of these complexes reveals that some inhibitors 
do not bind the catalytic zinc ion, but they only tightly occupy the S1’ 
pocket. Furthermore, these so called allosteric inhibitors possess a very 
peculiar shape that allow them to explore also an adjacent cavity named 
S1’*, which is unique among all the other MMPs. In these cases, the 
secondary and tertiary structures of the enzyme in general resemble those 
described for MMP13 crystallized with zinc binding inhibitors,13 except in 
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the S1’-specificity loop.14 It is evident that the non-zinc binding MMP13 
inhibitors confer an ordered structure to the S1’-specificity loop that is 
otherwise flexible and poorly defined. Particularly, the most active 
allosteric inhibitor, a methylquinazoline-dione compound, cocrystallized in 
2OZR pdb structure (Fig 1),15 does not interact with zinc ion but instead 
binds deep within the S1’-specificity loop of the protein and extends past 
this pocket out toward solvent. The benzyl ester points toward the substrate 
binding cleft but overlaps only slightly with the space that would be 
occupied by a P1’ leucine amino acid side chain in productively bound 
substrates or in non-selective peptidic MMP inhibitors such as GM-6001. 
This binding mode is consistent with a non-competitive mechanism of 
inhibition and contrasts with the substrate competitive inhibition expected 
for MMP inhibitors that bind to the catalytic zinc ion. In addition to not 
binding the catalytic zinc ion, this inhibitor does not occupy space within 
the substrate binding cleft of MMP-13. Its inhibitory potency and target 
specificity can be explained by complementarities of the inhibitor and the 
accommodating S1’-specificity loop of MMP13 in which it binds. This 
structural information represents the molecular underpinnings for the 
identification and/or the design of novel, selective and potent allosteric 
inhibitors.   
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Figure 1. Crystal structure 2OZR with the most active allosteric inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Pag. 
14 
 
  
1.3 State-of-the-art Methodologies 
 
In the early stage of research of drug discovery programs, high-
throughput screening (HTS) procedures can be applied for hit identification 
in large small molecule databases. In the past decade, in silico screening 
has been extensively used to reduce the number of compounds going into 
HTS, reducing time and costs for hit finding. In this respect, Virtual 
Screening (VS) is a technique now commonly used in drug discovery 
programs for lead finding and optimization and for scaffold hopping.16 In 
such an approach, a collection of potential candidate compounds is 
screened against a target protein or a reference molecule in order to select a 
subset of compounds for effective experimental screening. The selection 
can be done using a wide range of VS methods, either ligand- or target-
based when the three-dimensional (3D) structure of the target protein is 
available. 
The classical straightforward concept aiming at identifying analogues 
by comparing the physicochemical, structural, or pharmacophoric 
properties of a known active molecule with that of compounds in a 
collection has been massively applied during the last decades. Initially, 
these ligand-based virtual ligand screening (LBVLS) methods were based 
on simple 2D descriptors or fingerprints17 derived from the structure of the 
reference active compound and compared to the corresponding descriptors 
of database compounds using a similarity metric, such as the Tanimoto 
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coefficient (Tc). These methods were generally efficient, very fast, and 
provided as a result hits sharing a common chemotype with the active 
molecule used as the reference.18 To increase the structural diversity of the 
hits provided by LBVLS methods and thus to perform “scaffold-hopping” 
(i.e., change the chemotype, keep the activity19), different methods using 
more sophisticated 3D descriptors have later been developed, such as 
pharmacophore screening20 or shape similarity searching.21 
In pharmacophore screening, the knowledge of a set of aligned 
known active compounds is required, in contrast to shape similarity search 
methods that only require the structure of a single active compound. Shape 
similarity search methods thus appear as the LBVLS methods of choice 
when the structure of only few compounds is available. 
Finally, when the structure of the target in complex with a ligand is 
available, structure-based virtual ligand screening (SBVLS) methods like 
docking/scoring22 or structure-based pharmacophore screening23 are 
generally preferred.  
In this thesis work the author explores the proficiency of ROCS and 
Autodock 4.0 programs for the fast and effective identification of novel 
bioactive inhibitors of MMP-13 from two different databases.  
ROCS is a fast shape comparison application, based on the idea that 
molecules have similar shape if their volumes overlay well and any volume 
mismatch is a measure of dissimilarity. It uses a smooth Gaussian function 
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to represent the molecular volume,24 so it is possible to routinely minimize 
to the best global match. 
ROCS is a powerful virtual screening tool which can rapidly identify 
potentially active compounds with a similar shape to a known lead 
compound.25 The high speed of ROCS enables the screening of entire 
multi-conformer corporate collections in a single day on a single processor. 
Recent work indicates that ROCS is competitve with, and often superior to, 
structure-based approaches in virtual screening,26,27 both in terms of overall 
performance and consistency.28 ROCS alignments to crystallographic 
conformations have also been useful in pose prediction in the absence of a 
protein structure.29 
 On the other hand, AutoDock 4.030 has been used as a suite of 
automated docking tools. As one of the most widely used docking 
program, it is designed to predict how small molecules, such as substrates 
or drug candidates, bind to a receptor of known 3D structure. AutoDock 
actually consists of two main programs: AutoDock performs the docking of 
the ligand to a set of grids describing the target protein; AutoGrid pre-
calculates these grids. AutoDock 4.0 is faster than earlier versions, and it 
allows sidechains in the macromolecule to be flexible. AutoDock 4.0 has a 
free-energy scoring function that is based on a linear regression analysis, 
the AMBER force field, and a large set of diverse protein-ligand 
complexes with known inhibition constants. This novel force field (FF), 
accounting for an improved thermodynamic model, allows to more 
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accurately simulate the ligand/receptor binding process in comparison to 
the older version. 
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             II. Results and Discussion. 
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2.1  Receptor-Based Virtual Screening. AutoDock4. 
 
To date, eighteen X-ray structures of MMP-13 have been released in 
the Protein Data Bank. Besides that co-crystallized with TIMP-2 (PDB 
code: 2E2D), all the others were co-crystallized with organic inhibitors 
such as the diphenylether sulfone RS-130830 (PDB code 830C). A 
superposition of all X-ray structures on the alpha carbon atoms, using 830C 
as reference structure, shows that the protein folding and the catalytic loops 
shape are highly superimposable, and that in the catalytic site the large 
majority of the residues are all preserved in the side chain conformations. 
Thus, only the enzyme structure 830C, which has the lower resolution 
(1.60 Å), was selected for our VS experiment. As docking program for the 
VS, we used the Autodock program (AD4), which has been extensively 
and successfully employed in multiple VS campaigns undertaken by our 
research group.31 AD4 was applied to virtually screen the Life Chemicals 
database, a collection of six thousands non-redundant drug-like compounds 
selected to provide the broadest pharmacophore coverage. Prior to docking 
experiments, the entire Life Chemicals database was processed with the 
ZINC protocol leading to a total of 7769 molecules (see Experimental 
section for details).  The results of the VS on the Life Chemical database, 
were then sorted on the basis of the predicted binding free energies 
(∆GAD4) which in our case ranged from -3.93 to -15.61 kcal/mol. A scoring 
filter was set arbitrarily to -10.5 kcal/mol so as to retain 23% of the docked 
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solutions. The top 1800 compounds in their predicted binding poses were 
selected for visual inspection. In order to obtain compounds endowed with 
an inhibitory potency against MMP-13, we discarded all the molecules for 
which AD4 did not predict coordination of the catalytic zinc. Then, in the 
attempt to find leads with a certain selectivity of action, for each inspected 
compound, the occupancy of the S1’ pocket has been evaluated, although it 
was not expected to be total due to the small size of the docked 
compounds. As last criterion of choice, we evaluated the attitude of each 
molecule to be chemically optimized. At the end of this process, a total of 
24 compounds of the Life Chemical Data Set were selected for further 
analysis. Two products were not available from the vendor, and two were 
not soluble at the test concentration, so a total of twenty compounds were 
used for biochemical assays. Initially, all compounds were screened at a 
concentration of 100 µM by fluorometric assay on recombinat enzyme. 
ARP100,32 a hydroxamate-based MMP inhibitor previously developed by 
our research group, was used in the same assay conditions as reference 
compound. To exclude any possible nonspecific/promiscuous inhibition of 
MMP-13 due to aggregate formation, we performed all the assays 
pertaining the active compounds in the presence of 0.05% Brij-35, a 
nonionic detergent similar to Triton X-100, as suggested by Shoichet et 
al.33 Five ligands, out of the twenty tested, provided considerable inhibition 
of MMP-13 activity and were characterized in detail (see Experimental 
Methods). All other compounds that did not cause detectable inhibition at 
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100 µM concentrations were not further investigated (see SI for chemical 
structures). Table 1 lists structures, Life Chemicals codes, AD4 binding 
free energies and the MMP-13 IC50 of the novel inhibitors which ranges 
from 9 to 140 µM. The IC50 values were deduced from the non linear 
regression analysis of the log dose response curves. 
As shown in Table 1, all inhibitors scaffolds are structurally diverse 
from each other and from any known MMPIs. With the exception of 5 (and 
maybe 4, see paragraph “Active Compounds Binding Modes and Hints for 
Lead Optimization”), all active compounds possess a carboxylate function 
as ZBG. Compound 5 which holds a dimethoxybenzene as ZBG retains a 
certain activity although his IC50 (140 µM) is higher than all of the 
carboxylate-containing inhibitors. Very recently, Novartis researchers 
reported that a series of carboxylic acids such as the MMP-13 inhibitor 
24f34 were orally available and equipotent to the most potent hydroxamic 
acid based inhibitors in in vivo models of cartilage protection. Thus, some 
key physicochemical properties of our five leads were compared to those 
of 24f. Table 2 lists pKa, ClogP, ClogD, and TPSA data, which were 
calculated in silico35 as useful descriptors to estimate ionization, 
lipophilicity, and polarity. As shown in Table 2, with the exception of 5, 
which seems to be the least drug-like compound, all other inhibitors 
possess an average value of ClogP ranging from 0.89 to 3.32 and a ClogD 
and a TPSA very similar to that of 24f. Thus, with the exception of 5, all 
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the others seem to be ideal leads, for which the S1’ substituent could be 
easily extended and/or modified. 
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Table 1. Structures, Labels, AD4 Binding Free Energies and 
IC50 of MMP-13 inhibitors identified with VS Experiments. 
Chemical 
Structure 
Life Chemicals 
Code 
∆GAD4 
(Kcal/mol) 
IC50a 
(µM) 
O O
N
HN
S
OH
O
1 
F0920-6501 -13.33 9 
N
S O
O
OH
O
2 
F1074-0280 -13.12 22 
O
HO
O NH
H
N S
O
 
3 
F1204-0078 -10.96 67 
O
O
S
N
O
S
COOH
4 
F1542-0089 -12.11 120 
N
S O
ON
N
 
5 
F0807-0342 -10.5 140 
a IC50 values represent the concentration required to produce 
50% enzyme inhibition. 
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Table 2. Physicochemical Property Predictions 
of Compounds 1-5 and 24f. 
Compd pKa a ClogP b ClogD c TPSA (Å) d 
1 3.91 3.32 0.11 119.96 
2 3.89 2.6 -0.61 99.98 
3 3.68 0.89 -2.56 119.75 
4 3.62 2.91 -0.42 137.37 
5 - 5.55 5.55 71.71 
24fe 2.55 3.39 -0.13 158.86 
a
 pKa predictions refers to the ZBG. b Calculated 
n-octanol/ water partition coefficient. c Calculated 
distribution coefficient at pH=7.4. d Topological 
polar surface area.e Orally active carboxylic acid-
derived MMP-13 inhibitor used for comparison 
purpose34. 
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2.2   Biological evaluation 
 
 The inhibitory activity of the five novel leads was evaluated (Table 
3) against a panel of MMP isozymes (MMP-1, -2, -3, 13, -14), some of 
which are implicated in cartilage degradation. Over the five inhibitors, two 
(1 and 4) are definitely more active on MMP-13 showing appreciably 
weaker activity on all the other tested enzymes (Table 3). In this respect, 
both compounds represent appealing leads amenable of structural 
modification to develop selective MMP-13 inhibitors. Inhibitors 3, and 5 
are equally active on MMP-13 and MMP-14. The two compounds show 
inhibitory activity also towards MMP-2. In this respect, it is not clear 
whether this inhibitory profile is beneficial in terms of protecting cartilage 
degradation. Actually, the role of MMP-2 activity itself in the pathogenesis 
of OA is unclear. Interestingly, mRNA levels of MMP-2 are increased in 
OA patients compared to normal controls, suggesting that MMP-2 may 
play a role in this disease.36 On the other hand, MMP-2-null mice exhibit a 
more severe arthritic phenotype than wild type mice in antigen-induced 
arthritis, suggesting that the total loss of MMP-2 activity is unfavorable.37 
Differently, compound 2 shows a certain preference for MMP-2 (IC50 = 2.7 
µM) and could be developed as novel antitumor agent.  
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Table 3. In Vitroa Activity (IC50 µM Values) of the novel zinc-binders 
MMP-13 inhibitors towards diverse MMPs 
Compd Life Chemicals Code MMP-1 MMP-2 MMP-3 MMP-13 MMP-14 
1 F0920-6501 400±150 67±3.0 110±15 9±0.5 51±7.0 
2 F1074-0280 93±8.0 2.7±0.2 110±26 22±0.6 21±2.0 
3 F1204-0078 114±23 61±7.0 77±21 67±10 55±4.0 
4 F1542-0089 860±110 350±38 850±200 120±8 310±18 
5 F0807-0342 360±46 120±14 230±24 140±10 150±18 
a
 Assays were run in triplicate. The final values given here are the mean ± SD of three 
independent experiments. 
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2.3 Active Compounds Binding Modes and Hints for 
Lead Optimization. 
 
Besides the carboxylate function, which, with the exception of 5, is a 
conserved feature of all active inhibitors, the five compounds deeply differ 
in their chemical structures. Indeed, in 1, the carboxylate moiety is directly 
attached to a benzene ring, in 2 this portion is linked to a thiazolidindione 
nucleus by a propyl-linker, while in 3 and 4 a oxymethylene and a 
methylene bridge, respectively, link the carboxylate group to a benzene and 
thioxothiazolidinone ring, respectively. Regardless the structural 
dissimilarities among the aforementioned ligands, all of them are 
characterized by a small number of rotatable bonds (ranging from 0 to 4). 
Indeed, the rigidity of 1 allows the proper orientation of the ZBG to chelate 
the catalytic zinc ion and the P1’group into the S1’ pocket (see Figure2). 
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Figure 2. Docked conformations of 1 in the MMP-13 catalytic site. 
Hydrogens are omitted for the sake of clarity. Ligands carbon atoms are 
displayed in golden, and key binding site residues as cyan sticks.  
 
The imidazolethione ring is in a suitable position to establish a π -π 
interaction with H119 side chain. The  micromolar IC50 for this compound 
might be due  to the non-optimized interaction between the P1’ group and 
the S1’ pocket. The selectivity of 1 towards the MMP-13 is surely 
ascribable to the bulky chromenone nucleus located into the unusually 
large S1’specificity pocket. In fact, although MMP-13 and -14 possess a 
S1’ specificity loop of the same length, the latter has a narrower shaped S1’ 
pocket, due to the substitution of T245 and T247 in MMP-13 with Q262 
and M264 in MMP-14. This hypotheses is confirmed by inhibitor 2 (Fig 
3a), which shows the same activity on MMP-13 and MMP-14 possessing a 
thin olefinic chain ending with a phenyl ring which is unable to fill the 
roomy S1’pocket. Differently from inhibitor 2, compound 3 has a small 
and polar P1’ group, and this is the reason for the lower activity and 
selectivity for MMP-13 with respect to 1 and 2. However in 3 (Fig 3b), the 
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thioxoimidazolidinone ring could be substituted with groups featuring 
shapes and electrostatic propertied able to favorably interact with the 
peculiar S1’ tunnel of MMP-13. Especially for this compound, the 
extension of the P1’ group is certainly a priority step. 
 
 
Figure 3. Docked conformations of 2 (a) and 3 (b) in the MMP-13 catalytic 
site. 
 
 
As regards compound 4 (Fig 4a), molecular docking unambiguously 
indicate that the ZBG would be the carboxylate group and not the 
rhodanine ring via the thiazolidine sulfur atom, as previously found for 
Anthrax Lethal Factor inhibitors,38 which have in common with compound 
4 both the  rhodanine ring and the carboxylate group. However, a search in 
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the Cambridge Structural Databases shows that, at least in absence of any 
receptor structure, the carboxylate moiety prevails onto the rhodanine ring 
in the coordination of metal ions. Thus, prior of any rational optimization, 
further studies have to be conducted in order to assess the real binding 
mode of 4 in the MMP-13 active site. 
Inhibitor 5 (Fig 4b), is the weakest inhibitor (IC50 on MMP-13=140 
µM) on the entire panel of MMPs tested, although it is the only one whose 
P1’ group is able to make some contacts with the entrance residues of the 
S1’ pocket like P139, V116, as well as a parallel π-stacking with the H119. 
The thiazolidine ring makes some lipophilic contacts with the S1’ pocket 
floor residues (L81 and L82), while the N-benzylidene group projects itself 
towards the beta carbons of the Y141 and the I140.  
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Figure 4. Docked conformations of 4 (a) and 5 (b) in the MMP-13 catalytic 
site. 
 
In this case, the low activity is ascribable to the presence of a putative 
weak zinc ion chelator (dimethoxybenzene) and to the fact that it has been 
tested as a mixture of diastereoisomers. Thus, separation and testing of 
each single diastereoisomer, together with the substitution of the weak 
chelator moiety with a stronger one, could be the first step of the lead 
optimization process of this inhibitor. Subsequent steps could include 
proper substitutions of both phenyl rings to enhance the interaction with 
the S1’ and S3’ pockets. 
Thus, generally speaking, none of these compounds has such an 
extended P1’ group to occupy the whole S1’ tunnel of the MMP-13, 
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neither the P1’ are well-optimized to interact with the pocket. This is 
certainly the reason for the inhibitory activities in the range of µM. 
However, a rationally designed lead optimization project will surely 
increase the experimental IC50’s. In fact, even if less potent than 
hydroxamate-based inhibitors, carboxylates could be a valid alternative to 
this moiety. This weaker zinc-binder could allow to have selective 
inhibition if present in properly optimized structures. In order to verify the 
reliability of the proposed binding modes, the de-carboxylated analogue of 
compound 1 has been synthetized and subjected to binding assay. 
Intriguingly, the IC50 of this analogue turns out to be 177 µM, proving that 
our molecules were actually zinc binders as predicted by the docking 
program. Furthermore, for compound 1, which show a pretty good 
selectivity profile, lead optimizations have been carried out. 
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2.4   Lead Optimization. BOMB Analysis. 
 
 
 
At this point, a full substituent scan was indicated for replacement of 
each aromatic hydrogen in the 2-H-cromen-2-one core of compound 1. 
This was carried out with the in-home program BOMB (Biochemical and 
Organic Model Builder, Prof. William Jorgensen, Yale University, New 
Haven CT, USA). 
A standard protocol for a substituent scan with BOMB is to replace 
each hydrogen of a core with 10 small groups that have been selected for 
difference in size, electronic character, and hydrogen-bonding patterns: Cl, 
CH3, NH2, OH, CH2NH2, CH2-OH, CHO, CN, NHCH3, and OCH3. To 
begin, the structure of 1 bound to MMP-13 was built with BOMB using the 
AutoDock best scored pose and the structure of MMP-13 from the 830C 
PDB file. BOMB was then used to build the 50 complexes corresponding 
to the replacement of each phenyl hydrogen in the core with the 10 small 
groups. This revealed that the top-5 scoring analogs are dominated by 
substitution of either chlorine or oxygen group at the 6- and 8- position in 
the cromenone ring. Given this information, synthesis of compounds 10-13 
in Table 4 was carried out. Binding assay of compounds having both 
positions combinatorially substituted are already ongoing. These latter 
compounds are supposed to have inhibitor activity in nM range. 
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Table4. Chemical structure, BOMB score and inhibitor activity of 
compound 1 and the prepared compounds. 
 
 
 
 
 
 
Chemical 
Structure W Z 
BOMB 
Score IC50(mM) 
1 H H 0 14 
10 OH H -3.0851 5.5 
11 OCH3 H -2.9863 5.2 
12 H OCH3 -3.0431 3.2 
13 H Cl -3.4067 2.6 
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2.5   Ligand-Based VS. ROCS 
 
 
 
With the information available for the receptor structure regarding the 
unique S1’* pocket, we decided to identify small molecule MMP-13 
inhibitors through virtual screening using a ligand-based approach called 
ROCS. As a starting point for the ROCS search, we chose the 
methylquinazoline-dione allosteric inhibitor co-crystallized in 2OZR pdb 
structure. The X-ray crystallographic conformation of the ligand was used 
as a query for ROCS. To identify a novel MMP-13 small molecule 
inhibitors, ROCS shape-based searches were performed on Maybridge 
collections. The chemical/or color force field (CFF), Mills Dean, was 
added to the shape matching procedure during the searches. In other words, 
after finding the best alignment based on the shape, the program calculates 
the color force field score (color) to measure chemical complementarities, 
and to refine shape-based superimpositions based on chemical similarity. A 
scaled color value is calculated by taking a hit’s actual score value and 
dividing it by the color score of the query molecule against itself. The score 
used for ranking the hit list in this experiment is combo score that is the 
sum of the shape Tanimoto coefficient and the scaled color value. Since 
both shape Tanimoto coefficient and the scaled color are in the range of 0 
and 1, the combo score has a value from 0 to 2. Virtual screening hits were 
selected based on the minimum combo score of 1.2 in the ROCS searches. 
Thus, 1500 molecules were post-processed with AD4. The binding pocket 
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was defined using the crystallographic coordinates of the query (residues 
within 10 Å from the ligand) and only the best ranked 500 molecules were 
then visual inspected. In order to obtain compounds endowed with an 
inhibitory potency against MMP-13, all the molecules possessing a central 
rigid core, with 2 aromatic groups at the two opposite sides of the latter, 
were retained. Then, for each molecule, the quality of the core has been 
evaluated on the basis of the interactions established by the query with the 
MMP-13 enzyme. Particularly, it has been investigated the attitude to form 
hydrogen bonds with the backbone nitrogens of Thr224, Thr226 and 
Met232 within the S1’-specificity loop, whereas it has been considered of 
great importance for the two aromatic regions, their ability to establish pi-
interactions with His201 and Tyr223 in the S1’ pocket, and with Tyr225 
and Phe231 within the S1’* cavity. As last criterion of choice, we 
evaluated the attitude of each molecule to be chemically optimized. After 
the visual inspection, 40 molecules were finally submitted for testing with 
the consideration of chemical diversity. Primary binding assays, conducted 
as mentioned in the previous paragraph, identified four initial hits having 
inhibitor activity which ranges from 14 to 93 µM (Table 5). The ROCS hits 
and the query molecule have substantially different chemistry but 
reasonably high shape similarity. The inhibitory activity of the three most 
active leads was evaluated (Table 6) against a panel of MMP isozymes 
(MMP-1, -2, -13, -14), as well as for the leads found through the Receptor-
Based VS. Over the three inhibitors, compound 6 is definitely more active 
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on MMP-13 showing the best selectivity profile among the nine hits found 
in this work. In this respect, this compound probably represents the most 
promising lead to develop selective MMP-13 inhibitors with inhibitor 
activity in nM range. In order to proceed with a lead optimization cycle, a 
crystal structure of the ligand-protein complex is strictly required 
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Table 5. Structures, Labels and IC50 of MMP-13 inhibitors identified with VS 
Experiments. 
Chemical 
Structure 
Maybridge 
Codes 
IC50a 
(µM) 
6 
SO4817 14 
7 
DP00965 76 
8 
BTB08190 85 
9 
KM08338 93 
a IC50 values represent the concentration required to produce 
50% enzyme inhibition. 
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Table 6. In Vitroa Activity (IC50 µM Values) of the novel allosteric MMP-
13 inhibitors towards diverse MMPs 
Compd Maybridge Code MMP-1 MMP-2 MMP-13 MMP-14 
6 SO4817 710±110 440±52 14±2.4 290±8.4 
7 DP00965 120±9.7 95±8.7 76±5.5 116±8.8 
8 BTB08190 300±35 150±16 85±7.1 200±8.8 
a
 Assays were run in triplicate. The final values given here are the mean ± SD 
 of three independent experiments. 
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Experimental Section 
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Databases Preparation 
 
 For the in silico screening, the Life Chemicals database39 and the 
Maybridge database were used. These libraries are a collection of small 
compounds carefully selected to provide the broadest pharmacophore 
coverage for a total of 6000 and 70000 non-redundant molecules, 
respectively. The databases were uploaded on ZINC server40 as 1D smiles 
strings and processed with the ZINC protocol. This protocol filters-out 
molecules with molecular weight greater than 700, calculated LogP greater 
than 6 and less than −4, number of hydrogen-bond donors, hydrogen-bond 
acceptors, and rotatable bonds greater than 6, 11, and 15 respectively. It 
also removes all molecules containing “exotic” atoms (i.e. different from 
H, C, N, O, F, S, P, Cl, Br, or I). Moreover it allows the creation of all 
stereoisomers, tautomers and correctly protonated forms of the molecules 
between pH 5 and 9.5. The protocol outcome from the server was a file 
containing 7769 and 79229 compounds, respectively.  
 
Selection of the MMP-13 X-ray Structure for VS 
experiment and Protein Preparation 
 
Eighteen X-ray structures of MMP-13 have been released in the 
Protein Data Bank (PDB). A superposition of all X-ray structures on the 
alpha carbon atoms, using 830C as reference structure, shows that the 
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protein folding and the catalytic loops shape are highly superimposable and 
that in the catalytic site, the large majority of the residues are all preserved 
in the side chain conformations. Thus, only the enzyme structure 830C, 
which has the lower resolution (1.60 Å), was selected for our VS 
experiment. From this structure, all water molecules, ions and the inhibitor 
were removed from the binding site. All hydrogen atoms were added to the 
protein structure using ADT,41 and to the catalytic Zn ion present in the 
active site a +2 charge was assigned. 
 
Receptor-Based Virtual Screening Calculations 
 
 Docking calculations were performed with version 4.0 of the 
AutoDock software package as implemented through the graphic user 
interface AutoDockTools (ADT 1.4.6). All compounds of the Life 
Chemical diversity set together with the 830C structure of MMP-13 were 
converted to AutoDock format files (.pdbqt) using ADT. The docking area 
was defined by a box, centered on the catalytic zinc. Grids (dimension of 
60 Å × 65 Å × 60 Å) were then generated for 13 ligand atom types 
(sufficient to describe all atoms in the selected database) with the help of 
AutoGrid4 using a grid spacing of 0.375 Å. For each ligand of the Life 
Chemical diversity set, 100 separate docking calculations were performed. 
Each docking calculation consisted of 1 × 107 energy evaluations using the 
Lamarckian genetic algorithm local search (GALS) method. A low-
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frequency local search in accordance with the method of Solis and Wets 
was applied to docking trials to ensure that the final solution represents a 
local minimum. Each docking run was performed with a population size of 
150, and 300 rounds of Solis and Wets local search were applied, with a 
probability of 0.06. A mutation rate of 0.02 and a crossover rate of 0.8 
were used to generate new docking trials for subsequent generations. The 
docking results from each of the 100 calculations were clustered on the 
basis of root-mean square deviation (rmsd 2 Å) between the Cartesian 
coordinates of the ligand atoms and were ranked on the basis of the free 
energy of binding. The top-ranked compounds were visually inspected for 
good chemical geometry. Finally, as a last criterion of selection, we 
introduced the visual inspection of the putative best ranking ligand/receptor 
complexes. In this regard, we decided to discard all the molecules for 
which AD4 did not predict coordination of the catalytic zinc in order to 
obtain compounds of a certain potency. Another selection criterion resided 
in the occupancy of the S1’ pocket, in the attempt to obtain a selectivity of 
action towards the MMP-13. Pictures of the modelled ligand/enzyme 
complexes together with graphic manipulations were rendered with UCSF 
Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco.42 
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Ligand-Based OMEGA/ROCS Calculations 
 
 ROCS uses atom centered Gaussian functions parametrized to 
provide close approximations to hard sphere volumes. In ROCS, shape-
similarity is evaluated by maximizing the volume overlap between the 
reference active compound and a single conformation of a query molecule 
using the Tanimoto coefficient. In version 2.3.1, used in this study, a “color 
force field” represents physicochemical properties in addition to the shape 
component. The conformational search of the different query compounds 
(up to 100 conformers per compound) has been carried out prior to all the 
calculations using OMEGA, version 2.1.33 
 
 
BOMB Analysis 
 
BOMB creates analogs by adding substituents to a core that has been 
placed in a binding site.3a A thorough conformational search is performed 
for each analog, and the position, orientation, and dihedral angles for the 
analog are optimized using the OPLS-AA force field for the protein and 
OPLS/CM1A for the analog.8 The protein is rigid except for optimization 
of the terminal dihedral angles for side chains with hydrogen-bonding 
groups (e.g., the OH of tyrosine and the carboxylate group of aspartate). 
The resultant conformer for each analog with the lowest energy is then 
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evaluated with a docking-like scoring function. The current scoring 
function has been trained to reproduce experimental activity data for 339 
complexes of HIV-RT, COX-2, FK506 binding protein (FKBP), and p38 
kinase. The scoring function only contains five descriptors that were 
obtained by linear regression: the octanol/water partition coefficient for the 
analog as computed by QikProp (QPlogPo/w), the amount of hydrophobic 
surface area for the protein that is buried upon complex formation 
(¢FOSAP), the number of potential hydrogen-bond donating hydrogens in 
the analog (HBDNL), the number of nonconjugated amides in the analog, 
and the number of “bad” protein-analog contacts in the complex (NBAD). 
The latter represent structural mismatches between two atoms within 4 Å, 
typically between a potential hydrogen-bonding oxygen or nitrogen and a 
saturated carbon atom or between a potential hydrogen-bond accepting O 
or N and another such atom or an aryl carbon atom. Interestingly, (a) the 
most significant descriptor is QPlogPo/w, which alone yields a fit with an 
r2 of 0.47, and (b) inclusion of energetic results from full conjugate-
gradient optimizations of the complexes created by BOMB was found to 
have little impact on the accuracy of the scoring. Although the BOMB 
scoring is still under development, the current version provides a useful 
evaluation of potential activity. 
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Chemistry 
 
 The purity of the five hits that were essential to the conclusions 
drawn in the text were determined by HPLC on a Merck Hitachi D-7000 
liquid chromatograph equipped with a Discovery C18 column (250 mm x 
4.6 mm, 5 µm particle size) and a UV/vis detector setting at λ=250 nm.  
 
Biology. Materials and Methods. 
 
 Recombinant human MMP-14 catalytic domain was a kind gift of 
Prof. Gillian Murphy (Department of Oncology, University of Cambridge, 
UK). Pro-MMP-1, pro-MMP-2, pro-MMP-3, and pro-MMP-13 were 
purchased from Calbiochem. APMA was from Sigma-Aldrich. All 
compounds were subjected to combustion analysis prior to be tested for 
their inhibitory activity, to verify their consistence with a purity of at least 
95%. ARP100 was synthesized at Department of Pharmaceutical Sciences 
(Pisa, Italy) according to the previously described procedure.32 All other 
chemicals were of reagent grade. 
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Enzyme activation.  
 
Proenzymes were activated immediately prior to use with p-
aminophenylmercuric acetate (APMA 2 mM for 1 h at 37 °C for MMP-2, 
APMA 2 mM for 2 h at 37 °C for MMP-1, 1 mM for 30 min at 37 °C for 
MMP-13). Pro-MMP-3 was activated with trypsin 5 µg/mL for 30 min at 
37 °C followed by soybean trypsin inhibitor 62 µg/mL. 
 
Enzyme inhibition assays.  
 
For assay measurements, the purchased compound stock solutions 
(10 mM in DMSO) were further diluted for each MMP in the fluorimetric 
assay buffer (FAB: Tris 50 mM, pH = 7.5, NaCl 150 mM, CaCl2 10 mM, 
Brij 35 0.05% and DMSO 1%). Activated enzyme (final concentration 0.56 
nM for MMP-2, 0.3 nM for MMP-13, 5 nM for MMP-3, 1 nM for MMP-
14cd, and 2.0 nM for MMP-1) and inhibitor solutions were incubated in the 
assay buffer for 4 h at 25 °C. After the addition of 200 µM solution of the 
fluorogenic substrate Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-
Lys(Dnp)-NH2 (Sigma) for MMP-3 and Mca-Lys-Pro-Leu-Gly-Leu-
Dap(Dnp)-Ala-Arg-NH2 (Bachem) for all the other enzymes in DMSO 
(final concentration 2 µM), the hydrolysis was monitored every 15 sec for 
15 min recording the increase in fluorescence (λex = 325 nm, λem = 395 
nm) using a Molecular Devices SpectraMax Gemini XS plate reader. The 
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assays were performed in triplicate in a total volume of 200 µL per well in 
96-well microtitre plates (Corning, black, NBS). The MMP inhibition 
activity was expressed in relative fluorescent units (RFU). Percent of 
inhibition was calculated from control reactions without the inhibitor. The 
inhibitory effect of the tested compounds was routinely estimated at a 
concentration of 100 µM towards MMP-13. Those derivatives found to be 
active were tested at additional concentrations and IC50 was determined 
using at least five concentrations of the inhibitor causing an inhibition 
between 10% and 90%, using the formula: Vi/Vo = 1/(1 + [I]/ IC50), 
where Vi is the initial velocity of substrate cleavage in the presence of the 
inhibitor at concentration [I] and Vo is the initial velocity in the absence of 
the inhibitor. Results were analyzed using SoftMax Pro software43 and 
Origin 6.0 software. 
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Conclusions 
 
This paper reports the identification of structurally non-classic MMP-
13 inhibitors by means of two different in silico screening methods. 
Experimental evaluation of a restricted number of candidates (60), which 
were selected by visual inspection of the poses predicted for the best 
scoring compounds, led to the identification of five novel zinc-chelating 
non-hydroxamate inhibitors, and four allosteric inhibitors, structurally 
distinct from those already reported. Eight of these compounds may 
provide scaffolds upon which to develop compounds with more desirable 
properties, such as selectivity of action and oral availability. Moreover, 
their discovery supports the use of virtual screening as a successful method 
for the discovery of novel MMPIs with unexpected structures. 
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